Results 31 to 40 of about 662,207 (147)

SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria [PDF]

Importance  Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce chronic kidney disease (CKD) progression in individuals with type 2 diabetes, CKD, or heart failure.
Wanner, Christoph, Cherney, David Z. I., Perkovic, Vlado, Inzucchi, Silvio E, Anker, Stefan D, Zannad, Faiez, Fletcher, Robert A, McMurray, John JV, Cherney, David ZI, Jardine, Meg J., Patel, Siddharth M, McGuire, Darren K., Solomon, Scott D., Fletcher, Robert A., Sabatine, Marc S., Staplin, Natalie, Sardell, Rebecca J, Wheeler, David C, Docherty, Kieran F., Inzucchi, Silvio E., Vaduganathan, Muthiah, Solomon, Scott D, Butler, Javed, Bhatt, Deepak L., Jardine, Meg J, Sabatine, Marc S, Bhatt, Deepak L, McCausland, Finnian R, Neal, Bruce, Mahaffey, Kenneth W, McCausland, Finnian R., Herrington, William G., Anker, Stefan D., McMurray, John J. V., Docherty, Kieran F, Neuen, Brendon L., Heerspink, Hiddo J. L., Haynes, Richard, Patel, Siddharth M., Packer, Milton, Neuen, Brendon L, Mahaffey, Kenneth W., McGuire, Darren K, Heerspink, Hiddo JL, Sardell, Rebecca J., Herrington, William G, Wheeler, David C.   +46 more
core   +1 more source

Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure [PDF]

, 2019
BACKGROUND AND OBJECTIVES: Recent studies have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure (HF)-associated hospitalization and mortality in patients with diabetes.
고영국
core   +1 more source

The effects of SGLT2 inhibitor side chain structure on its function and side effects

, 2022
Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by hyperglycemia. The pathophysiology of T2DM is complex but it is known that cells cannot use insulin effectively. The initial treatment for T2DM focuses on a healthy lifestyle, however,
Nuñez de la Rosa, Ana Karen
core  

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury. [PDF]

, 2016
Dapagliflozin, a new type of drug used to treat diabetes mellitus (DM), is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Although some studies showed that SGLT2 inhibition attenuated reactive oxygen generation in diabetic kidney the role of SGLT2 ...
Ki-Ryang Na, Jin Young Jeong, Hyunsu Choi, Kang Wook Lee, Dae Eun Choi, Yoon-Kyung Chang, Beom Jin Lim   +6 more
core   +2 more sources

The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study

Cardiovascular Diabetology, 2020
Background Clinical trials have shown the cardiovascular protective effect of sodium–glucose cotransporter-2 (SGLT2) inhibitors and reduced hospitalization for heart failure. However, no study has investigated the association between SGLT2 inhibitors and
Hung-Yi Chen, Jing-Yang Huang, Wun-Zhih Siao, Gwo-Ping Jong   +3 more
doaj   +1 more source

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

, 2014
Type 2 diabetes is increasing in prevalence worldwide, and hyperglycemia is often poorly controlled despite a number of therapeutic options. Unlike previously available agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors offer an insulin ...
Joshua J Neumiller
core   +1 more source

Blood Pressure‐Lowering Effect of SGLT2 Inhibitors in Patients Without Antihypertensive Treatment: A Real‐World Data Analysis

The Journal of Clinical Hypertension
Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have demonstrated blood pressure (BP)‐lowering effects; however, most studies included patients taking antihypertensive medications.
Reina Ito, Michihiro Satoh, Hideaki Hashimoto, Hiroki Nobayashi, Seiya Izumi, Maya Toyama, Yutaro Iwabe, Yuya Suzuki, Takuo Hirose, Shingo Nakayama, Takahisa Murakami, Masato Sasaki, Hirohito Metoki   +12 more
doaj   +1 more source

On‐label use of sodium–glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes

Journal of Diabetes Investigation, 2021
Aims/Introduction This study aimed to investigate the risk of diabetic ketoacidosis (DKA) in insulin‐treated type 1 diabetes patients administered sodium–glucose cotransporter 2 (SGLT2) inhibitors in real‐world clinical practice. Materials and Methods We
Takeshi Horii, Yoichi Oikawa, Koichiro Atsuda, Akira Shimada   +3 more
doaj   +1 more source

Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria

Diabetology & Metabolic Syndrome, 2020
Background We compared the effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease (CKD) classified by degree of albuminuria.
Akinobu Nakamura, Hideaki Miyoshi, Hiraku Kameda, Kumiko Yamashita, Yoshio Kurihara   +4 more
doaj   +1 more source

Survey to Specify SGLT2 Inhibitor Choice in T2DM Management [PDF]

, 2022
Objective: There are no major head-to-head comparative studies till date to compare the differences in glycemic efficacy, safety, or cardio-renal effects within SGLT2 inhibitors.
Iyer, Rahul N.; Department of Medical Affairs, Cipla Ltd, Mumbai, India, Joshi, Radhika M.; Department of Medical Affairs, Cipla Ltd, Mumbai, India, Adsule, Samir M.; Department of Medical Affairs, Cipla Ltd, Mumbai, India, Ghosal, Samit; Department of Diabetes and Endocrinology, Nightingale Hospital, Kolkata, India   +3 more
core   +1 more source